Semaglutide vs Retatrutide: GLP-1 vs Triple Agonist for Weight Loss

Semaglutide is today's best-established weight-loss peptide; retatrutide is the most powerful one still in trials. One activates a single incretin receptor, the other activates three. This guide compares them on mechanism, weight-loss magnitude, approval status, and safety — and explains why "more powerful" doesn't automatically mean "better choice right now." For the single-agent deep dives, see What Is Semaglutide? and What Is Retatrutide?.

The Short Answer

Retatrutide produced greater average weight loss in mid-stage trials (~24% at 48 weeks, Phase 2) than semaglutide does (~15% at 68 weeks, STEP 1) — but retatrutide is investigational and semaglutide is FDA-approved with landmark cardiovascular-outcome data. Semaglutide is a GLP‑1 agonist; retatrutide is a triple GLP‑1/GIP/glucagon agonist. If you need an approved therapy with proven heart benefit now, semaglutide is the only option of the two. If you're tracking the next leap in efficacy, retatrutide is the one to watch. (Retatrutide Phase 2 — NEJM, STEP 1 — NEJM)

Mechanism: One Receptor vs Three

• Semaglutide is a GLP‑1 receptor agonist — appetite suppression, slowed gastric emptying, glucose-dependent insulin secretion. One pathway, deeply validated. (STEP 1 — NEJM)
• Retatrutide is a triple agonist of GLP‑1 + GIP + glucagon receptors. It adds GIP (which appears to amplify GLP‑1's metabolic effects) and glucagon agonism (which can raise energy expenditure and mobilize liver fat) on top of the GLP‑1 appetite brake. (Retatrutide Phase 2 — NEJM)

Think of it as a "metabolic triad": GLP‑1 curbs appetite, GIP potentiates, and glucagon turns up the energy-burn dial. That third dial is what separates retatrutide from both semaglutide and the dual agonist tirzepatide — and the leading explanation for its larger average loss in early trials.

Side-by-Side Snapshot

Figures: STEP 1, Retatrutide Phase 2.

Efficacy: Bigger Numbers, Earlier Stage

Retatrutide's Phase 2 obesity study reported mean weight loss up to ~24% at 48 weeks, with the weight curve still trending downward at study end — suggesting room for more with longer treatment. Semaglutide's STEP 1 delivered ~14.9% at 68 weeks, and ~86% of participants lost at least 5% of body weight. (Retatrutide Phase 2 — NEJM, STEP 1 — NEJM)

The crucial caveat: these are cross-trial comparisons, not a head-to-head. Different participants, different protocols, different stages of development. There is no published direct trial of retatrutide vs semaglutide. (For an example of how much a real head-to-head can clarify things, see the tirzepatide-vs-semaglutide SURMOUNT-5 trial in Semaglutide vs Tirzepatide.)

Where Semaglutide Wins Today

• It's approved and available. Retatrutide can only be accessed through clinical trials; semaglutide is broadly prescribed.
• Proven cardiovascular benefit. The SELECT trial showed semaglutide cut major adverse cardiovascular events by 20% in people with obesity and established CVD — a hard outcome retatrutide has not yet demonstrated. (SELECT — NEJM)
• Long-term safety record and an oral option (Rybelsus).
• Maintenance data. Long-term weight-maintenance and durability data for retatrutide await Phase 3 readouts.

Where Retatrutide Is Promising

• Largest average weight loss of any incretin agent reported so far in mid-stage trials.
• Glucagon-driven energy expenditure and exploratory signals of lipid improvement (e.g., non-HDL-C reductions). (Retatrutide Phase 2 — NEJM)
• Caveat — heart rate. Phase 2 noted a transient rise in heart rate that peaked around 24 weeks before declining; its long-term clinical significance is still under study. (Retatrutide safety — PubMed)

Which Should You Choose?

• Need an approved drug, proven heart benefit, or an oral option → semaglutide.
• Watching the efficacy frontier / considering a trial → retatrutide, pending Phase 3 results.
• Want the strongest currently approved option → that's tirzepatide, the dual agonist that sits between these two; see Semaglutide vs Tirzepatide and Retatrutide vs Tirzepatide.

For either drug, weight regain on discontinuation is the rule, and medical supervision is essential.

FAQ

Is retatrutide better than semaglutide?
Retatrutide produced greater average weight loss in Phase 2 trials (~24% at 48 weeks) than semaglutide (~15% at 68 weeks), but retatrutide is still investigational and lacks long-term and cardiovascular-outcome data. Semaglutide is FDA-approved with proven heart benefit. So "better" depends on whether you weigh raw efficacy or approval, access, and evidence depth. (Retatrutide Phase 2, STEP 1)

What's the difference in how they work?
Semaglutide activates a single incretin receptor (GLP‑1). Retatrutide activates three receptors — GLP‑1, GIP, and glucagon. The added glucagon agonism can increase energy expenditure, which is the main reason retatrutide shows larger average weight loss in early trials. (Retatrutide Phase 2)

Is retatrutide available by prescription?
No. Retatrutide is investigational and is in Phase 3 (the TRIUMPH program). It is not FDA-approved and can only be accessed through clinical trials. Semaglutide, by contrast, is widely available by prescription as Ozempic and Wegovy.

Does retatrutide have cardiovascular benefits like semaglutide?
Semaglutide has demonstrated a 20% reduction in major adverse cardiovascular events in the SELECT trial. Retatrutide's cardiovascular-outcomes trials are still ongoing, so it has not yet shown a comparable hard cardiovascular benefit. (SELECT — NEJM)

Why might retatrutide raise heart rate?
In Phase 2 trials, retatrutide caused a transient increase in heart rate that peaked around 24 weeks and then declined. The mechanism may relate to its glucagon and GLP‑1 signaling. Its long-term clinical significance is still being evaluated in Phase 3. (Retatrutide safety)

How does this compare to tirzepatide?
Tirzepatide is the dual GLP‑1/GIP agonist that sits between semaglutide (single) and retatrutide (triple). It is FDA-approved and, in a head-to-head trial, outperformed semaglutide on weight loss. Retatrutide adds a third (glucagon) pathway and shows even larger early numbers, but is not yet approved. See Semaglutide vs Tirzepatide and Retatrutide vs Tirzepatide.

Next Steps

For reconstitution math and dosing tables, see the SEMA 5 mg Protocol and Retatrutide 10 mg Protocol, or run the numbers in the peptide dosage calculator. To complete the picture, read Retatrutide vs Tirzepatide and Semaglutide vs Tirzepatide.

Bottom line: semaglutide is the proven, approved, heart-protective choice today; retatrutide is the higher-ceiling option still proving itself in Phase 3.